Brilique: Can AZ polish a third-to-market drug?
This article was originally published in Scrip
Today's management upheaval at AstraZeneca underlines the desperate measures that CEO Pascal Soriot will need if he is to put the company on a sound footing. And the sorry story of one product – the oral antiplatelet Brilique/Brilinta – illustrates just how ineffective scrabbling around the fringes of drug commercialization can be.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.